AXELIA ONCOLOGY
Axelia Oncology is a biopharmaceutical company aiming to transform the treatment of checkpoint-insensitive cancers by the activation of TLR2/6 engagement of the innate immune response.
AXELIA ONCOLOGY
Industry:
Biopharma Health Care Health Diagnostics Pharmaceutical
Founded:
2014-01-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.axeliaoncology.com
Total Employee:
11+
Status:
Active
Contact:
+61 3 9657 0700
Email Addresses:
[email protected]
Total Funding:
11.7 M AUD
Investors List
Uniseed
Uniseed investment in Series A - Axelia Oncology
Brandon Capital
Brandon Capital investment in Series A - Axelia Oncology
Official Site Inspections
http://www.axeliaoncology.com
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Axelia Oncology"
About - Axelia Oncology
Axelia Oncology is a biopharmaceutical company aiming to transform the treatment of checkpoint insensitive cancers through the activation of TLR2/6 engagement of the innate immune response.See details»
Axelia Oncology - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +61 3 9657 0700 Axelia Oncology is a biopharmaceutical company aiming to transform the treatment of checkpoint-insensitive …See details»
Contact Us - Axelia Oncology
Address. Axelia Oncology Pty Ltd Level 9, 31 Queen Street Melbourne, VIC 3000 Austrailia. Email. [email protected]. Phone +61 3 9657 0700See details»
Axelia Oncology - PitchBook
Axelia Oncology General Information Description. Operator of a biotechnology company intended to develop a novel innate immunomodulator. The company uses a district mechanism of action …See details»
Axelia Oncology - Products, Competitors, Financials, Employees ...
Axelia Oncology takes its TLR2/6 agonist into the clinic to harness the innate immune system. Jan 16, 2024. Jan. 16, 2024 Axelia Oncology Pty Ltd. was spun out of Ena Respiratory Pty. Ltd., …See details»
Axelia Oncology - Overview, News & Similar companies - ZoomInfo
View Axelia Oncology (www.axeliaoncology.com) location in Victoria, Australia , revenue, industry and description. Find related and similar companies as well as employees by title and much …See details»
Axelia Oncology - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Jan 1, 2020: Series A - Axelia …See details»
Axelia Oncology - VentureRadar
"Axelia Oncology is dedicated to combating checkpoint-insensitive tumors by harnessing the innate immune system. Their lead candidate, AXA-042, is a novel TLR2/6 agonist that drives …See details»
Axelia Oncology - Company Profile - Tracxn
Nov 27, 2024 Axelia Oncology - Developer of immunotherapy agents for the treatment of cancer. Raised funding from 1 investor. Axelia Oncology has 2860 competitors.See details»
Series A - Axelia Oncology - 2020-01-01 - Crunchbase
Axelia Oncology raised $8213396 on 2020-01-01 in Series A. Start Free Trial . Chrome ExtensionSee details»
Axelia - Brandon Capital
San Francisco. Brandon Capital LLC. 1 Letterman Ave, Suite C3-330. San Francisco, CA 94129. Phone +61 3 9657 0700. Email: [email protected]See details»
Axelia Oncology Stock Price, Funding, Valuation, Revenue
See Axelia Oncology funding rounds, investors, investments, exits and more. Evaluate their financials based on Axelia Oncology's post-money valuation and revenue.See details»
Axelia Oncology - BIO International Convention 2024
Please enter the code shown above * Submit Contact Request. LoadingSee details»
Axelia Oncology | Stoic VC - Venture Capital for Frontier Research
Xelia Oncology is developing safe and effective therapies for cancer patients using the body’s own immune system.See details»
Research & Development - Axelia Oncology
Once-a-week AXA-042 treatment inhibits CT26 tumour growth in vivo; AXA-042 potentiates anti-PD-1 Ab treatment response, leading to 40% complete regressionsSee details»
Publications Archive | Axelia Oncology
Systemic administration of AXA-042, a novel TLR2/6 agonist, reshapes the tumor microenvironment, as revealed by single cell sequencing analysisSee details»
Apex Oncology
Jan 12, 2019 Our mission and vision. Founded in 2007, Apex Oncology is dedicated to the provision of specialised services to the pharmaceutical industry and the development of new …See details»
Presentation at the 2022 AACR Annual Meeting | Axelia Oncology
© 2024 Axelia Oncology. All Rights Reserved | Accessibility Statement | Privacy Policy | Cookie PolicyAccessibility Statement | Privacy Policy | Cookie PolicySee details»
AXA-042 - A Novel Systemic TLR2/6 Agonist for Anti-Tumor Therapy.
Title: 42x60 PowerPoint Presentation Author: PosterPresentations.com Subject: Research poster presentation template Keywords: 42x60 Powerpoint poster template, scientific poster template, …See details»